Vancouver, BC – January 25, 2024
Variational AI, a leader in generative AI drug discovery, has announced a collaboration with Merck Research Labs to evaluate its Enki™ generative AI platform for designing novel, selective small molecules. The project is supported by the CQDM Quantum Leap program, strengthening innovation in AI-driven drug development.
Harnessing Generative AI for Drug Design
Merck will use Variational AI’s Enki™ platform to design and assess new small molecules targeting specific therapeutic areas. Enki™ operates as a foundation model for molecular design, utilizing generative AI methods similar to those in image generation. It transforms Target Product Profiles (TPPs) into optimized small molecule candidates through AI-driven synthesis prediction.
Transforming Drug Discovery with AI
One of Enki™’s biggest advantages is that it eliminates the need for companies to build proprietary AI systems. Instead, chemists can input TPPs and receive novel, synthesizable, and selective lead-like compounds in a matter of days. This significantly accelerates the discovery process and streamlines lead optimization efforts.
Strategic Industry Impact
Handol Kim, CEO of Variational AI, said:
“Merck’s adoption of Enki™ underscores the growing role of generative AI in pharmaceutical R&D. This collaboration demonstrates how AI can reshape drug discovery, providing Merck with novel molecular structures optimized for its pipeline.”
The collaboration is further supported by CQDM’s Quantum Leap program, which facilitates partnerships between Canadian biotech innovators and global pharmaceutical companies.
Jesse Paterson, Senior Director of Business Development at CQDM, added:
“These collaborations are crucial for advancing AI-driven breakthroughs in drug development.”
About Variational AI
Variational AI is at the forefront of generative AI in drug discovery, enabling faster and more affordable access to potent and synthesizable small molecule leads for biopharmaceutical companies.
More on this announcement
About CQDM
CQDM is a Canadian not-for-profit biopharmaceutical consortium that accelerates the development and translation of innovative therapeutic technologies by supporting collaborative R&D between startups and global pharmaceutical leaders.
By
